Subtopic Deep Dive

BMP Signaling Dysregulation in Heterotopic Ossification
Research Guide

What is BMP Signaling Dysregulation in Heterotopic Ossification?

BMP Signaling Dysregulation in Heterotopic Ossification refers to aberrant activation of the bone morphogenetic protein (BMP) pathway, particularly via ACVR1 receptor mutations, driving pathologic bone formation in soft tissues.

This subtopic centers on how dysregulated BMP signaling, often through ALK2/ACVR1, induces heterotopic ossification (HO) in conditions like fibrodysplasia ossificans progressiva (FOP). Key papers include Yu et al. (2008, 612 citations) showing BMP type I receptor inhibition reduces HO, and Kaplan et al. (2008, 388 citations) detailing FOP mechanisms. Over 10 listed papers span 2000-2019 with 200-1500+ citations each.

15
Curated Papers
3
Key Challenges

Why It Matters

Dysregulated BMP signaling drives HO in trauma, FOP, and progressive osseous heteroplasia, affecting mobility and quality of life. Yu et al. (2008) demonstrated dorsomorphin inhibits BMP receptors to block HO in mouse models of trauma and BMP overstimulation. Sanvitale et al. (2013) identified small molecule ALK2 inhibitors, advancing therapies for FOP where Kaplan et al. (2008) linked ACVR1 mutations to progressive ossification. Pathway modulation offers therapeutic promise across HO etiologies.

Key Research Challenges

Targeting Mutant ACVR1 Selectively

Inhibitors like those in Sanvitale et al. (2013) block wild-type and mutant ALK2/ACVR1, risking bone loss from normal BMP signaling. Yu et al. (2008) showed systemic BMP inhibition reduces HO but highlighted off-target effects in development. Selective mutant targeting remains unsolved for FOP therapy.

Inflammation-BMP Crosstalk Mechanisms

Inflammatory signals aberrantly activate BMP via ACVR1 in HO, as in trauma models from Meyers et al. (2019). Lees-Shepard et al. (2018) linked activin signaling in FAPs to FOP ossification, but precise triggers need clarification. Decoupling inflammation from BMP activation challenges prevention.

Translating Preclinical Inhibitors

SB-431542 and similar ALK inhibitors work in mouse HO models (Yu et al., 2008), but human FOP trials face delivery and flare-up issues per Pignolo et al. (2011). Kaplan and Shore (2000) noted POH progression despite interventions. Clinical efficacy lags preclinical promise.

Essential Papers

1.

TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease

Mengrui Wu, Guiqian Chen, Yiping Li · 2016 · Bone Research · 1.5K citations

2.

BMP type I receptor inhibition reduces heterotopic ossification

Paul B. Yu, Donna Y. Deng, Carol Lai et al. · 2008 · Nature Medicine · 612 citations

3.

TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation

Md Shaifur Rahman, Naznin Akhtar, Hossen Mohammad Jamil et al. · 2015 · Bone Research · 555 citations

Transforming growth factor-beta (TGF-β)/bone morphogenetic protein (BMP) plays a fundamental role in the regulation of bone organogenesis through the activation of receptor serine/threonine kinases...

4.

Bone Morphogenetic Proteins

Takenobu Katagiri, Tetsuro Watabe · 2016 · Cold Spring Harbor Perspectives in Biology · 493 citations

Bone morphogenetic proteins (BMPs), originally identified as osteoinductive components in extracts derived from bone, are now known to play important roles in a wide array of processes during forma...

5.

Heterotopic Ossification: A Comprehensive Review

Carolyn A. Meyers, Jeffrey Lisiecki, Sarah Miller et al. · 2019 · JBMR Plus · 456 citations

ABSTRACT Heterotopic ossification (HO) is a diverse pathologic process, defined as the formation of extraskeletal bone in muscle and soft tissues. HO can be conceptualized as a tissue repair proces...

6.

Fibrodysplasia ossificans progressiva

Frederick S. Kaplan, Martine Le Merrer, David L. Glaser et al. · 2008 · Best Practice & Research Clinical Rheumatology · 388 citations

7.

Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects

Robert J. Pignolo, Eileen M. Shore, Frederick S. Kaplan · 2011 · Orphanet Journal of Rare Diseases · 296 citations

Fibrodysplasia ossificans progressiva (FOP) is a severely disabling heritable disorder of connective tissue characterized by congenital malformations of the great toes and progressive heterotopic o...

Reading Guide

Foundational Papers

Start with Yu et al. (2008, 612 citations) for BMP receptor inhibition proof-of-concept in HO models, then Kaplan et al. (2008, 388 citations) for FOP genetics, and Sanvitale et al. (2013) for inhibitor chemistry.

Recent Advances

Lees-Shepard et al. (2018) on activin-FAPs in FOP; Meyers et al. (2019, 456 citations) comprehensive HO review linking BMP to etiologies.

Core Methods

ALK2/ACVR1 kinase inhibition (dorsomorphin, C++ compounds); mouse trauma/BMP injection HO models; activin signaling assays in fibro/adipogenic progenitors.

How PapersFlow Helps You Research BMP Signaling Dysregulation in Heterotopic Ossification

Discover & Search

Research Agent uses searchPapers('BMP signaling heterotopic ossification ACVR1') to retrieve Yu et al. (2008, 612 citations), then citationGraph reveals downstream works like Sanvitale et al. (2013), and findSimilarPapers expands to FOP models in Lees-Shepard et al. (2018). exaSearch queries 'ALK2 inhibitors HO preclinical' for inhibitor-focused literature.

Analyze & Verify

Analysis Agent applies readPaperContent on Yu et al. (2008) to extract dorsomorphin dosing in HO models, verifyResponse with CoVe cross-checks claims against Kaplan et al. (2008) FOP data, and runPythonAnalysis plots signaling pathway stats from BMP papers using pandas for citation-normalized impact. GRADE grading scores evidence strength for ALK inhibitor efficacy.

Synthesize & Write

Synthesis Agent detects gaps like selective ACVR1 inhibition via contradiction flagging between Yu et al. (2008) and Sanvitale et al. (2013), while Writing Agent uses latexEditText for HO pathway revisions, latexSyncCitations integrates 10+ papers, latexCompile generates figures, and exportMermaid diagrams BMP-ACVR1 cascades.

Use Cases

"Analyze BMP inhibitor dose-response data from Yu 2008 and plot HO reduction curves"

Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib extracts doses, fits curves, outputs HO inhibition plot with R² stats)

"Draft LaTeX review section on ACVR1 mutations in FOP HO with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText (writes section) → latexSyncCitations (adds Pignolo 2011, Kaplan 2008) → latexCompile (PDF preview of cited FOP mechanisms)

"Find GitHub repos with BMP signaling simulation code from HO papers"

Research Agent → paperExtractUrls (Yu 2008) → Code Discovery → paperFindGithubRepo → githubRepoInspect (pulls Python models of ALK2 inhibition kinetics for local run)

Automated Workflows

Deep Research workflow scans 50+ BMP/HO papers via searchPapers → citationGraph, producing structured report ranking ALK inhibitors by evidence (Yu 2008 prioritized). DeepScan's 7-step chain verifies ACVR1 mutation claims across Pignolo et al. (2011) and Lees-Shepard et al. (2018) with CoVe checkpoints. Theorizer generates hypotheses on inflammation-BMP links from Wu et al. (2016) and Meyers et al. (2019).

Frequently Asked Questions

What defines BMP signaling dysregulation in HO?

Aberrant BMP pathway activation via ACVR1/ALK2 mutations or overstimulation drives soft tissue ossification, as in FOP (Kaplan et al., 2008) and trauma HO (Yu et al., 2008).

What methods target BMP dysregulation?

Small molecule ALK2 inhibitors like dorsomorphin (Yu et al., 2008) and C++ compounds (Sanvitale et al., 2013) block receptor signaling in preclinical HO models.

What are key papers?

Yu et al. (2008, 612 citations) on receptor inhibition; Kaplan et al. (2008, 388 citations) on FOP; Sanvitale et al. (2013, 236 citations) on ALK2 inhibitors.

What open problems exist?

Selective inhibition of mutant ACVR1 without disrupting normal BMP (Sanvitale et al., 2013); mechanisms of activin-BMP crosstalk in FAPs (Lees-Shepard et al., 2018).

Research Heterotopic Ossification and Related Conditions with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching BMP Signaling Dysregulation in Heterotopic Ossification with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers